Intellia Therapeutics (NTLA) CFO granted stock options and RSUs

Rhea-AI Filing Summary

Dulac Edward J III reported acquisition or exercise transactions in this Form 4 filing.

Intellia Therapeutics EVP and CFO Edward J. Dulac III reported new equity awards. On March 1, 2026, he received a stock option for 87,543 shares of common stock and a grant of 61,280 shares of common stock in the form of restricted stock units.

The option was granted with 33% vesting on January 1, 2027, and the remaining 67% vesting in 24 substantially equal monthly installments after that date. Following the common stock award, his directly held common stock position increased to 160,963 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Dulac Edward J III

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	87,543	$0.00	--
Grant/Award	Common Stock	61,280	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 87,543 shares (Direct); Common Stock — 160,963 shares (Direct)

Footnotes (1)

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dulac Edward J III

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET, SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/01/2026		A		61,280	A	$0	160,963	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.78	03/01/2026		A		87,543		(2)	02/29/2036	Common Stock	87,543	$0	87,543	D

Explanation of Responses:

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

2. This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

	James Basta, attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did NTLA’s CFO report on March 1, 2026?

Intellia’s CFO Edward J. Dulac III reported equity awards on March 1, 2026. He received a stock option for 87,543 shares and a restricted stock unit grant representing 61,280 shares of Intellia Therapeutics common stock.

How many Intellia (NTLA) shares does the CFO own after this Form 4?

After the reported grant, Edward J. Dulac III directly owns 160,963 shares of Intellia common stock. This figure reflects his common stock position following the 61,280-share restricted stock unit award reported for March 1, 2026.

What are the vesting terms of the Intellia CFO’s new stock option?

The stock option granted to Intellia’s CFO vests over time. 33% vests on January 1, 2027, and the remaining 67% vests in 24 substantially equal monthly installments after that date, according to the Form 4 footnote.

Is the Intellia CFO’s Form 4 transaction a market purchase or a grant?

The reported transactions for Intellia’s CFO are grants, not market purchases. Both the 87,543-share stock option and the 61,280-share common stock award are coded as “A”, indicating grant, award, or other acquisition under the company’s equity compensation arrangements.

What type of equity award is the 61,280-share grant to Intellia’s CFO?

The 61,280-share grant to Intellia’s CFO consists of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Intellia common stock upon vesting, as described in the Form 4 footnote.

Does the Intellia CFO hold the reported shares directly or indirectly?

According to the Form 4, Edward J. Dulac III holds the reported securities directly. Both the stock option and the common stock position are marked with direct ownership, without any indication of intermediary entities or indirect ownership structures.